210 related articles for article (PubMed ID: 35075805)
1. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening.
Yuan B; Zhao X; Wang X; Liu E; Liu C; Zong Y; Jiang Y; Hou M; Chen Y; Chen L; Zhang Y; Wang H; Fu J
Clin Transl Med; 2022 Jan; 12(1):e678. PubMed ID: 35075805
[TBL] [Abstract][Full Text] [Related]
2. Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers.
Shiihara M; Ishikawa T; Saiki Y; Omori Y; Hirose K; Fukushige S; Ikari N; Higuchi R; Yamamoto M; Morikawa T; Nakagawa K; Hayashi H; Mizuma M; Ohtsuka H; Motoi F; Unno M; Okamura Y; Kinoshita K; Furukawa T
Eur J Cancer; 2021 May; 148():239-250. PubMed ID: 33752134
[TBL] [Abstract][Full Text] [Related]
3. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
[TBL] [Abstract][Full Text] [Related]
4. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
5. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
6. Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
Feng F; Cheng Q; Yang L; Zhang D; Ji S; Zhang Q; Lin Y; Li F; Xiong L; Liu C; Jiang X
Oncotarget; 2017 Jan; 8(3):5349-5360. PubMed ID: 28029662
[TBL] [Abstract][Full Text] [Related]
7. Personalized
Pauli C; Hopkins BD; Prandi D; Shaw R; Fedrizzi T; Sboner A; Sailer V; Augello M; Puca L; Rosati R; McNary TJ; Churakova Y; Cheung C; Triscott J; Pisapia D; Rao R; Mosquera JM; Robinson B; Faltas BM; Emerling BE; Gadi VK; Bernard B; Elemento O; Beltran H; Demichelis F; Kemp CJ; Grandori C; Cantley LC; Rubin MA
Cancer Discov; 2017 May; 7(5):462-477. PubMed ID: 28331002
[TBL] [Abstract][Full Text] [Related]
8. Patient-Derived Organoids of Cholangiocarcinoma.
Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
[TBL] [Abstract][Full Text] [Related]
9. ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway.
Nakamura T; Nishikawa Y; Shiokawa M; Takeda H; Yokode M; Matsumoto S; Muramoto Y; Ota S; Yoshida H; Okada H; Kuwada T; Marui S; Matsumori T; Maruno T; Uza N; Kodama Y; Hatano E; Seno H
J Pathol; 2023 Sep; 261(1):28-42. PubMed ID: 37345534
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
Zhang Y; Zuo C; Liu L; Hu Y; Yang B; Qiu S; Li Y; Cao D; Ju Z; Ge J; Wang Q; Wang T; Bai L; Yang Y; Li G; Shao Z; Gao Y; Li Y; Bian R; Miao H; Li L; Li X; Jiang C; Yan S; Wang Z; Wang Z; Cui X; Huang W; Xiang D; Wang C; Li Q; Wu X; Gong W; Liu Y; Shao R; Liu F; Li M; Chen L; Liu Y
J Hepatol; 2021 Nov; 75(5):1128-1141. PubMed ID: 34171432
[TBL] [Abstract][Full Text] [Related]
11. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
Calandrini C; Schutgens F; Oka R; Margaritis T; Candelli T; Mathijsen L; Ammerlaan C; van Ineveld RL; Derakhshan S; de Haan S; Dolman E; Lijnzaad P; Custers L; Begthel H; Kerstens HHD; Visser LL; Rookmaaker M; Verhaar M; Tytgat GAM; Kemmeren P; de Krijger RR; Al-Saadi R; Pritchard-Jones K; Kool M; Rios AC; van den Heuvel-Eibrink MM; Molenaar JJ; van Boxtel R; Holstege FCP; Clevers H; Drost J
Nat Commun; 2020 Mar; 11(1):1310. PubMed ID: 32161258
[TBL] [Abstract][Full Text] [Related]
12. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.
Li J; Xu H; Zhang L; Song L; Feng D; Peng X; Wu M; Zou Y; Wang B; Zhan L; Hua G; Zhan X
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2637-2647. PubMed ID: 31598791
[TBL] [Abstract][Full Text] [Related]
13. Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes.
Nepal C; Zhu B; O'Rourke CJ; Bhatt DK; Lee D; Song L; Wang D; Van Dyke AL; Choo-Wosoba H; Liu Z; Hildesheim A; Goldstein AM; Dean M; LaFuente-Barquero J; Lawrence S; Mutreja K; Olanich ME; Lorenzo Bermejo J; ; Ferreccio C; Roa JC; Rashid A; Hsing AW; Gao YT; Chanock SJ; Araya JC; Andersen JB; Koshiol J
J Hepatol; 2021 May; 74(5):1132-1144. PubMed ID: 33276026
[TBL] [Abstract][Full Text] [Related]
14. Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells.
Wu Y; Meng D; Xu X; Bao J; You Y; Sun Y; Li Y; Sun D
BMC Cancer; 2021 Apr; 21(1):433. PubMed ID: 33879096
[TBL] [Abstract][Full Text] [Related]
15. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening identified miR-7-2-3p and miR-29c-3p as metastasis suppressors in gallbladder carcinoma.
Lu K; Feng F; Yang Y; Liu K; Duan J; Liu H; Yang J; Wu M; Liu C; Chang Y
J Gastroenterol; 2020 Jan; 55(1):51-66. PubMed ID: 31562534
[TBL] [Abstract][Full Text] [Related]
17. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
[TBL] [Abstract][Full Text] [Related]
18. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived renal cell carcinoma organoids for personalized cancer therapy.
Li Z; Xu H; Yu L; Wang J; Meng Q; Mei H; Cai Z; Chen W; Huang W
Clin Transl Med; 2022 Jul; 12(7):e970. PubMed ID: 35802820
[TBL] [Abstract][Full Text] [Related]
20. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
Sachs N; de Ligt J; Kopper O; Gogola E; Bounova G; Weeber F; Balgobind AV; Wind K; Gracanin A; Begthel H; Korving J; van Boxtel R; Duarte AA; Lelieveld D; van Hoeck A; Ernst RF; Blokzijl F; Nijman IJ; Hoogstraat M; van de Ven M; Egan DA; Zinzalla V; Moll J; Boj SF; Voest EE; Wessels L; van Diest PJ; Rottenberg S; Vries RGJ; Cuppen E; Clevers H
Cell; 2018 Jan; 172(1-2):373-386.e10. PubMed ID: 29224780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
